Fulcrum Therapeutics price target raised to $15 from $13 at Piper Sandler

Piper Sandler raised the firm’s price target on Fulcrum Therapeutics to $15 from $13 and keeps an Overweight rating on the shares. The firm notes Fulcrum will report top-line Phase III REACH data comparing 15mg BID losmapimod to placebo in 260 facioscapulohumeral muscular dystrophy patients in Q4. REACH is over 90% powered on the primary endpoint of Reachable Work Space. If positive, losmapimod could be the first novel FSHD medicine to gain approval, and Piper believes would emerge as standard oral therapy. Separately, Fulcrum is re-initiating the Phase Ib study of monotherapy pociredir for the treatment of higher risk sickle cell disease patients who experienced prior hydroxyurea and another advanced therapy.